Raia Drogasil (RADL3) Stock Overview
Engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines in Brazil. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for RADL3 from our risk checks.
RADL3 Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Raia Drogasil S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R$18.43 |
| 52 Week High | R$27.42 |
| 52 Week Low | R$16.21 |
| Beta | 0.013 |
| 1 Month Change | 2.50% |
| 3 Month Change | -0.27% |
| 1 Year Change | 0.69% |
| 3 Year Change | -30.48% |
| 5 Year Change | -24.37% |
| Change since IPO | 2,761.06% |
Recent News & Updates
Narrative Update • Aug 08
RADL3: Higher Margin Outlook Will Support Bullish Long Term Repricing
Analysts lowered their price target for Raia Drogasil from R$32.00 to R$31.00, citing updated assumptions that now reflect slightly different discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News No recent news items for Raia Drogasil were identified in the provided sources as of 6 Aug 2026.Analysis Article • Aug 07
Analysts Have Made A Financial Statement On Raia Drogasil S.A.'s (BVMF:RADL3) Second-Quarter Report
It's been a good week for Raia Drogasil S.A. ( BVMF:RADL3 ) shareholders, because the company has just released its...
Narrative Update • Jul 25
RADL3: Future Returns Will Depend On Margins And P/E Expectations
Analysts have trimmed their Raia Drogasil price target slightly to R$25.45 from R$26.52, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margins and future P/E expectations. What’s in the News No recent company specific news items for Raia Drogasil were identified in the provided sources.
Narrative Update • Jul 11
RADL3: Margin Headwinds And Higher P/E Will Shape A Balanced Outlook
Analysts have trimmed their Raia Drogasil fair value estimate from R$19.32 to R$18.07, reflecting updated assumptions around slightly higher projected revenue growth, a lower profit margin, a modestly reduced discount rate and a somewhat higher future P/E multiple. What's in the News for Raia Drogasil No recent Raia Drogasil specific news items were provided in the available sources.Narrative Update • Jun 27
RADL3: Future Returns Will Depend On Margins And P/E Expectations
Analysts have lowered their Raia Drogasil price target from R$28.05 to R$26.52, reflecting updated assumptions for revenue growth, profit margins and forward P/E levels. What’s in the News for Raia Drogasil No recent company specific news for Raia Drogasil has been identified in the available primary sources.Recent updates
Narrative Update • Aug 08
RADL3: Higher Margin Outlook Will Support Bullish Long Term Repricing
Analysts lowered their price target for Raia Drogasil from R$32.00 to R$31.00, citing updated assumptions that now reflect slightly different discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News No recent news items for Raia Drogasil were identified in the provided sources as of 6 Aug 2026.Analysis Article • Aug 07
Analysts Have Made A Financial Statement On Raia Drogasil S.A.'s (BVMF:RADL3) Second-Quarter Report
It's been a good week for Raia Drogasil S.A. ( BVMF:RADL3 ) shareholders, because the company has just released its...Narrative Update • Jul 25
RADL3: Future Returns Will Depend On Margins And P/E Expectations
Analysts have trimmed their Raia Drogasil price target slightly to R$25.45 from R$26.52, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margins and future P/E expectations. What’s in the News No recent company specific news items for Raia Drogasil were identified in the provided sources.Narrative Update • Jul 11
RADL3: Margin Headwinds And Higher P/E Will Shape A Balanced Outlook
Analysts have trimmed their Raia Drogasil fair value estimate from R$19.32 to R$18.07, reflecting updated assumptions around slightly higher projected revenue growth, a lower profit margin, a modestly reduced discount rate and a somewhat higher future P/E multiple. What's in the News for Raia Drogasil No recent Raia Drogasil specific news items were provided in the available sources.Narrative Update • Jun 27
RADL3: Future Returns Will Depend On Margins And P/E Expectations
Analysts have lowered their Raia Drogasil price target from R$28.05 to R$26.52, reflecting updated assumptions for revenue growth, profit margins and forward P/E levels. What’s in the News for Raia Drogasil No recent company specific news for Raia Drogasil has been identified in the available primary sources.Analysis Article • Jun 20
Is Now The Time To Put Raia Drogasil (BVMF:RADL3) On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Narrative Update • Jun 13
RADL3: Slightly Lower Multiple Will Shape A More Balanced Outlook
Analysts have trimmed their Raia Drogasil price target slightly to around R$19.32 from about R$19.78, reflecting updated assumptions on discount rate, revenue growth, profit margin, and future P/E. What's in the News No recent company specific news items or key developments were provided in the sources above.Narrative Update • May 30
RADL3: Updated Fair Value View Will Temper Expectations Despite Firmer Margins
Analysts have reduced their fair value estimate for Raia Drogasil from approximately R$22.16 to about R$19.78, citing updated assumptions for revenue growth, profit margins, and future P/E levels. Valuation Changes Fair Value: Reduced from R$22.16 to R$19.78, reflecting updated assumptions in the model.Narrative Update • May 13
RADL3: Future Returns Will Depend On Margins And P/E Expectations
Raia Drogasil's analyst price target has inched down slightly from R$28.12 to R$28.05, as analysts fine tune their models around a modestly different discount rate, revenue outlook, profit margin assumptions, and future P/E expectations. Valuation Changes Fair Value: R$28.12 to R$28.05, a small downward adjustment that reflects the updated inputs.Narrative Update • Apr 28
RADL3: Future Returns Will Hinge On Margins And Rating Assumptions
Analysts have adjusted their R$ price target for Raia Drogasil slightly higher to R$28.12, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. Valuation Changes Fair Value: R$27.89 updated to R$28.12, indicating a slightly higher assessed price level.Narrative Update • Apr 14
RADL3: Fair Value View Suggests Higher Margins Will Limit Future Upside
Analysts now set a slightly lower price target for Raia Drogasil at around R$22.16 versus about R$22.17 previously, reflecting updated views on the discount rate, revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: R$22.17 to R$22.16, a very small downward adjustment in the modelled estimate.Narrative Update • Mar 31
RADL3: Higher Margin Outlook Will Likely Restrain Future Share Upside
Analysts have raised their price target on Raia Drogasil from R$19.64 to R$22.17, citing updated assumptions that combine slightly different revenue growth and discount rate inputs with a higher projected profit margin and broadly similar future P/E expectations. Valuation Changes Fair Value: R$19.64 to R$22.17, a small upward adjustment in the implied valuation range.Narrative Update • Mar 17
RADL3: Future Returns Will Hinge On Margins And Capital Choices
Analysts now see fair value for Raia Drogasil at around R$27.89 versus R$27.06 previously, reflecting updated assumptions for slightly lower revenue growth, a modestly higher profit margin, an adjusted discount rate, and a revised future P/E outlook. Valuation Changes Fair Value: updated from R$27.06 to R$27.89, reflecting the revised set of assumptions across growth, margins, discount rate and future P/E.Narrative Update • Mar 03
RADL3: Higher Margin Outlook Will Support Bullish Long Term Repricing
Analysts have raised their price target on Raia Drogasil to R$32.00 from R$30.39, citing updated assumptions for revenue growth, profit margins and future P/E that slightly adjust the discount rate and support a higher estimated fair value. What's in the News Raia Drogasil announced a stock dividend of 1.020002244% scheduled for December 23, 2025 (Key Developments).Narrative Update • Feb 17
RADL3: Fair Value View Will Rely On Margins And Capital Decisions
Analysts have raised their Raia Drogasil price target slightly to R$27.06 from R$26.65, reflecting updated assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Raia Drogasil plans a stock dividend of 1.020002244% scheduled for December 23, 2025, which will slightly increase the number of shares you hold without requiring new cash outlay (Key Developments).Narrative Update • Feb 02
RADL3: Fair Value View Will Depend On Margins And Shareholder Actions
Analysts have nudged their fair value estimate for Raia Drogasil to R$26.65, up from about R$26.11, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. What's in the News Announced a stock dividend of 1.020002244% scheduled for December 23, 2025, giving shareholders additional shares instead of cash (Key Developments).Narrative Update • Jan 19
RADL3: Higher Profitability Assumptions Will Support Bullish Long Term Repricing
Analysts now see a modestly higher fair value for Raia Drogasil, lifting their price target from R$28.54 to R$30.39 as they weigh updated assumptions for revenue growth, profit margins and future P/E levels. What's in the News Raia Drogasil plans a stock dividend of 1.020002244% scheduled for December 23, 2025, which may slightly increase your share count over time (Key Developments).Analysis Article • Jan 16
Market Participants Recognise Raia Drogasil S.A.'s (BVMF:RADL3) Earnings
With a price-to-earnings (or "P/E") ratio of 32.3x Raia Drogasil S.A. ( BVMF:RADL3 ) may be sending very bearish...Narrative Update • Jan 05
RADL3: Profit Margins And Shareholder Actions Will Shape Future Performance
Analysts have lifted their fair value estimate for Raia Drogasil from R$24.65 to R$26.11, citing updated assumptions for revenue growth, profit margins and future P/E multiples as key drivers of the new price target. What's in the News Raia Drogasil plans a stock dividend of 1.020002244% scheduled for December 23, 2025, which will slightly increase the number of shares held by existing shareholders (Key Developments).Analysis Article • Dec 29
The Return Trends At Raia Drogasil (BVMF:RADL3) Look Promising
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Narrative Update • Dec 19
RADL3: Richer Earnings Multiple Will Likely Pressure Future Share Returns
Analysts have raised their price target on Raia Drogasil from approximately R$14.50 to about R$19.64, citing expectations of slightly faster revenue growth, modestly higher profit margins, and a richer future price to earnings multiple, despite a largely unchanged discount rate. What's in the News Raia Drogasil has scheduled a Special and Extraordinary Shareholders Meeting for December 22, 2025, to be held at Avenida Corifeu de Azevedo Marques, 3.097, in São Paulo, Brazil (company event filing).Analysis Article • Dec 11
Is Now The Time To Put Raia Drogasil (BVMF:RADL3) On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Narrative Update • Dec 05
RADL3: Profit Margins And Revenue Outlook Will Shape Future Performance
Analysts have nudged their price target for Raia Drogasil higher from R$23.92 to roughly R$24.65, citing slightly stronger expectations for revenue growth, improving profit margins and a modestly richer future P E multiple. What's in the News Raia Drogasil has scheduled a special and extraordinary shareholders meeting for December 22, 2025, to be held at Avenida Corifeu de Azevedo Marques, 3.097, Sao Paulo, Brazil (company filing).Analysis Article • Nov 26
Is Raia Drogasil (BVMF:RADL3) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrative Update • Nov 20
RADL3: Profit Margins And Revenue Outlook Will Influence Future Performance
Analysts have raised their price target for Raia Drogasil from R$22.25 to R$23.92. They cited increased profit margin projections despite a slightly reduced outlook for revenue growth.Narrative Update • Nov 03
RADL3: Aging Population And Digital Transformation Will Lift Retail Performance
Narrative Update on Raia Drogasil Analysts have slightly increased their price target for Raia Drogasil to R$22.25 from R$21.91. This change reflects modest improvements in projected revenue growth and profit margin, which contributed to a higher assessed fair value.Narrative Update • Oct 20
Brazil Aging Trends And Digital Channels Will Elevate Retail Performance
Narrative Update: Raia Drogasil Analyst Price Target Revision Analysts have raised their price target for Raia Drogasil from $21.58 to $21.91. They cite improved revenue growth projections and a marginally lower discount rate as key drivers of the upward revision.Narrative Update • Sep 27
Brazil Aging Trends And Digital Channels Will Elevate Retail Performance
Raia Drogasil’s slight price target reduction to R$21.58 primarily reflects a modest decrease in its expected future P/E ratio despite a marginal improvement in net profit margin. What's in the News Board approved payment of BRL 131.8 million in interest on equity, equating to BRL 0.076940867 per share, to be paid by December 5, 2025; no monetary restatement applicable.Analysis Article • Sep 14
The Return Trends At Raia Drogasil (BVMF:RADL3) Look Promising
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...Narrative Update • Sep 12
Brazil Aging Trends And Digital Channels Will Elevate Retail Performance
The slight upward revisions in both Raia Drogasil’s expected revenue growth and future P/E reflect improved growth prospects, leading analysts to raise their consensus price target from R$21.54 to R$22.06. What's in the News Board approved payment of BRL 131.8 million in interest on equity, equivalent to BRL 0.076940867 per share, to be paid by December 5, 2025; no monetary restatement applies.Narrative Update • Aug 28
Brazil Aging Trends And Digital Channels Will Elevate Retail Performance
Raia Drogasil's consensus price target has increased to R$21.21, with both its future P/E and discount rate remaining largely stable, indicating steady valuation assumptions amid the upward fair value revision. What's in the News Board approved payment of BRL 131.8 million in interest on equity, equivalent to BRL 0.076940867 per share, to be paid by December 5, 2025.Analysis Article • Aug 27
Here's Why Raia Drogasil (BVMF:RADL3) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Narrative • Nov 27
RD Saude's Expansion And Digital Investment Ignite Growth In The Health Market
Expansion and digital investment aim to increase market share and boost revenue via mature store growth and new store openings.Shareholder Returns
| RADL3 | BR Consumer Retailing | BR Market | |
|---|---|---|---|
| 7D | 5.1% | 4.5% | 2.0% |
| 1Y | 0.7% | -12.7% | 11.7% |
Return vs Industry: RADL3 exceeded the BR Consumer Retailing industry which returned -12.7% over the past year.
Return vs Market: RADL3 underperformed the BR Market which returned 11.7% over the past year.
Price Volatility
| RADL3 volatility | |
|---|---|
| RADL3 Average Weekly Movement | 5.5% |
| Consumer Retailing Industry Average Movement | 5.5% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in BR Market | 8.3% |
| 10% least volatile stocks in BR Market | 1.8% |
Stable Share Price: RADL3 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: RADL3's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1905 | 75,594 | Renato Raduan | rdsaude.com.br |
Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines in Brazil. The company sells its products through stores, telesales, and call centers. Raia Drogasil S.A. was founded in 1905 and is headquartered in São Paulo, Brazil.
Raia Drogasil S.A. Fundamentals Summary
| RADL3 fundamental statistics | |
|---|---|
| Market cap | R$32.23b |
| Earnings (TTM) | R$1.40b |
| Revenue (TTM) | R$46.53b |
23.0x
P/E Ratio0.7x
P/S RatioIs RADL3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RADL3 income statement (TTM) | |
|---|---|
| Revenue | R$46.53b |
| Cost of Revenue | R$32.44b |
| Gross Profit | R$14.10b |
| Other Expenses | R$12.69b |
| Earnings | R$1.40b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.80 |
| Gross Margin | 30.30% |
| Net Profit Margin | 3.02% |
| Debt/Equity Ratio | 47.4% |
How did RADL3 perform over the long term?
See historical performance and comparisonDividends
2.1%
Current Dividend Yield29%
Payout RatioDoes RADL3 pay a reliable dividends?
See RADL3 dividend history and benchmarks| Raia Drogasil dividend dates | |
|---|---|
| Ex Dividend Date | Apr 07 2026 |
| Dividend Pay Date | Dec 01 2026 |
| Days until Ex dividend | 139 days |
| Days until Dividend pay date | 99 days |
Does RADL3 pay a reliable dividends?
See RADL3 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/23 19:22 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Raia Drogasil S.A. is covered by 22 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andréa Aznar | BB Banco de Investimento S.A. |
| Robert Ford Aguilar | BofA Global Research |
| Marcio Osako | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |